GlassScriptPhysician profile
James M Metts
NPI 1871698183
$1,438.77
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $256 · 2021: $357 · 2022: $318 · 2023: $193 · 2024: $95.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $287.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $401.44 | 2019-2024 | |
| Tris Pharma INC | $318.12 | 2019-2023 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $167.67 | 2019-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $128.98 | 2020-2022 | |
| Corium, LLC | $106.23 | 2022-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $76.05 | 2021-2022 | |
| Kaleo, INC. | $57.38 | 2022 | |
| Adlon Therapeutics L.P. | $43.26 | 2020 | |
| Sanofi Pasteur INC. | $31.65 | 2022-2023 | |
| Sobi, INC | $22.73 | 2019 | |
| Merck Sharp & Dohme LLC | $21.93 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $18.92 | 2021 | |
| Nestle Healthcare Nutrition INC. | $16.50 | 2023 | |
| Sarepta Therapeutics, INC. | $14.06 | 2022 | |
| Glaxosmithkline, LLC. | $13.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Metts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.